Category Archives: TB

Petition asks BRICS to triple TB R&D funding

By on .

Global tuberculosis treatment advocates and activists are asking leaders of the five countries that are home to almost half of all tuberculosis illnesses and deaths to triple their funding for research and development of new medicines and technologies to prevent, diagnose, and treat the leading infectious disease killer worldwide, on a petition that will be […]

TB advocates call on organizations, leaders to work together, speed access to existing treatments for drug resistant tuberculosis

By on .

They would like an answer on March 24 When World TB Day next Tuesday commemorates the discovery in 1882 of the bacteria that causes the disease, announcements and op-ed pieces will note the progress that has been made since, and will certainly call for more. A group of 89 organizations that last week sent a […]

TAG’s TB drug guide aims to equip activists

By on .

While the impact of tuberculosis grew over the last decades of the 20th century, with drug resistant forms of the disease and HIV fueling its spread and slowing cures, the drugs used to treat TB have not changed. Bedaquiline and delaminid are the only new TB drugs to have been approved in over forty years, […]

TB drug approvals, distribution deal inches options forward, but MDR TB treatment access still uncertain where needed most

By on .

Last week’s developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility. That good news for multidrug-resistant TB patients, many of whom have run out of other options, was […]

Tuberculosis drug maker Sanofi drops price, easing access to shortened TB infection treatment

By on .

It was Christmas come early for publicly funded TB programs and for advocates of improved tuberculosis regimens when the maker of a rifapentine, a drug that can shorten treatment for tuberculosis infection from as much as nine months to three months announced Thursday it will drop its price for the medicine to a dollar a […]

TB treatment advocates to Sanofi pharmaceutical company on drug price: “We cry enough!”

By on .

A little more than four months ago, a collection of organizations and individuals concerned with the high price of rifapentine, a drug that could treat tuberculosis more quickly than other drugs, and also treat TB infection before it caused illness, wrote to Sanofi, the company that makes the medicine. Noting that government funding that had […]

Towards Zero Deaths: Roadmap for Childhood Tuberculosis builds on proven steps

By on .

For years the most helpless victims of tuberculosis have also been the least noticed, although they are estimated to comprise up to 10 percent — or more, as they often go uncounted as well — of people sick with the disease worldwide. They are children, younger that 15 years old, whose lives are taken when […]

Advocates, physicians to pharmaceutical company: lower price on government-supported drug, aid research

By on .

It has been heralded as an important step in ending the threat of tuberculosis in the United States, and one with ramifications for countries with higher incidence of the disease: a new drug to treat TB infection before it causes illness, treat it more quickly than current regimens. With standard treatment consisting of daily pills […]

With TB research threatened, doctors, patients, advocates and filmmakers spell out risks

By on .

At a recent conference of medical researchers, National Institute of Allergy and Infectious Diseases Director Anthony Fauci spelled out what lawmakers appear to be missing in their budget balancing efforts. “They don’t realize,” Fauci said, “that hitting biomedical research now is going to have an impact, three, four years from now.” So efforts to let […]

US TB drug shortages highlight global gaps

By on .

This is how small the world of infectious diseases can be, and how recent the distant past. The patient who ended up at Baltimore’s Health Department in April 2011 had been treated with apparent success for tuberculosis before, in Kenya, where he was from. But now, he had a strain of the disease that was […]